molecular profiling
Recently Published Documents


TOTAL DOCUMENTS

2150
(FIVE YEARS 654)

H-INDEX

83
(FIVE YEARS 12)

2022 ◽  
Vol 20 (1) ◽  
Author(s):  
Alexandra Lebedeva ◽  
Yulia Shaykhutdinova ◽  
Daria Seriak ◽  
Ekaterina Ignatova ◽  
Ekaterina Rozhavskaya ◽  
...  

Abstract Background A fraction of patients referred for complex molecular profiling of biopsied tumors may harbor germline variants in genes associated with the development of hereditary cancer syndromes (HCS). Neither the bioinformatic analysis nor the reporting of such incidental germline findings are standardized. Methods Data from Next-Generation Sequencing (NGS) of biopsied tumor samples referred for complex molecular profiling were analyzed for germline variants in HCS-associated genes. Analysis of variant origin was performed employing bioinformatic algorithms followed by manual curation. When possible, the origin of the variant was validated by Sanger sequencing of the sample of normal tissue. The variants’ pathogenicity was assessed according to ACMG/AMP. Results Tumors were sampled from 183 patients (Males: 75 [41.0%]; Females: 108 [59.0%]; mean [SD] age, 57.7 [13.3] years) and analysed by targeted NGS. The most common tumor types were colorectal (19%), pancreatic (13%), and lung cancer (10%). A total of 56 sequence variants in genes associated with HCS were detected in 40 patients. Of them, 17 variants found in 14 patients were predicted to be of germline origin, with 6 variants interpreted as pathogenic (PV) or likely pathogenic (LPV), and 9 as variants of uncertain significance (VUS). For the 41 out of 42 (97%) missense variants in HCS-associated genes, the results of computational prediction of variant origin were concordant with that of experimental examination. We estimate that Sanger sequencing of a sample of normal tissue would be required for ~ 1–7% of the total assessed cases with PV or LPV, when necessity to follow with genetic counselling referral in ~ 2–15% of total assessed cases (PV, LPV or VUS found in HCS genes). Conclusion Incidental findings of pathogenic germline variants are common in data from cancer patients referred for complex molecular profiling. We propose an algorithm for the management of patients with newly detected variants in genes associated with HCS.


Author(s):  
Tugba Kilic ◽  
Young Kwan Cho ◽  
Naebong Jeong ◽  
Ik-Soo Shin ◽  
Bob S. Carter ◽  
...  

2022 ◽  
Author(s):  
Salim Arslan ◽  
Xiusi Li ◽  
Julian Schmidt ◽  
Julius Hense ◽  
Andre Geraldes ◽  
...  

We present a public validation of PANProfiler (ER, PR, HER2), an in-vitro medical device (IVD) that predicts the qualitative status of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) by analysing the hematoxylin and eosin (H&E)-stained tissue scan. In public validation on 648 (ER), 648 (PR) and 560 (HER2) unseen cases with known biomarker status, the device achieves an accuracy of 87% (ER), 83% (PR) and 87% (HER2). The validation offers early evidence of the ability to predict clinically relevant breast biomarkers from an H&E slide in a relevant clinical setting.


RSC Advances ◽  
2022 ◽  
Vol 12 (3) ◽  
pp. 1479-1485
Author(s):  
Ben. J. Tickner ◽  
Sanna Komulainen ◽  
Sanna Palosaari ◽  
Janne Heikkinen ◽  
Petri Lehenkari ◽  
...  

SABRE hyperpolarisation enhances NMR signals of low concentration nicotine and acrolein and allows quantitative detection in electronic cigarette aerosol solutions.


Surgery ◽  
2022 ◽  
Vol 171 (1) ◽  
pp. 155-159
Author(s):  
Nasim T. Babazadeh ◽  
Tiffany J. Sinclair ◽  
Vikram Krishnamurthy ◽  
Judy Jin ◽  
Katherine B. Heiden ◽  
...  

2021 ◽  
pp. 106689692110701
Author(s):  
Nicholas J. Roig ◽  
Michelle Wu ◽  
Osvaldo Hernandez ◽  
Cheng Z. Liu ◽  
Tamar C. Brandler

Myopericytomas are uncommon tumors defined by their round to spindle shaped cells often arranged in a concentric pattern of perivascular growth. They are typically well-circumscribed, nodular, slow-growing lesions that occur in the soft tissue of the extremities. Here, we present a 30-year-old female with a 2.4 cm myopericytoma occurring in the deep lobe of the parotid gland. The diagnosis was made with detailed histopathologic and immunohistochemical findings and positive identification of the specific mutation for PDGFRβ p.Asp666Lys by next generation sequencing (NGS). This is the first case report of a parotid myopericytoma with a genetic testing that shows a particular mutation that has been linked to myopericytomatosis.


Sign in / Sign up

Export Citation Format

Share Document